首页 > 最新文献

Oncoimmunology最新文献

英文 中文
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration. 区域免疫机制增强腹腔注射的自体细胞癌疫苗的疗效。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-31 Epub Date: 2024-11-01 DOI: 10.1080/2162402X.2024.2421029
Ben Marwedel, Lorél Y Medina, Henning De May, Joshua E Adogla, Ellie Kennedy, Erica Flores, Eunju Lim, Sarah Adams, Eric Bartee, Rita E Serda

Widespread peritoneal dissemination is common in patients with gynecologic or gastrointestinal cancers. Accumulating evidence of a central role for regional immunity in cancer control indicates that intraperitoneal immunotherapy may have treatment advantages. This study delineates immune mechanisms engaged by intraperitoneal delivery of a cell-based vaccine comprised of silicified ovarian cancer cells associated with enhanced survival. Vaccine trafficking from the site of injection to milky spots and other fat-associated lymphoid clusters was studied in syngeneic cancer models using bioluminescent and fluorescent imaging, microscopy, and flow cytometry. Spectral flow cytometry was used to phenotype peritoneal immune cell populations, while bioluminescent imaging of cancer was used to study myeloid and T cell dependency, systemic immunity, and vaccine efficacy in models of disseminated high-grade serous ovarian and DNA mismatch-repair proficient microsatellite-stable colorectal cancer. Following intraperitoneal vaccination of mice with ovarian cancer, vaccine cells were rapidly internalized by myeloid cells, with subsequent trafficking to fat-associated lymphoid clusters. Tumor clearance was confirmed to be T cell-mediated, leading to the establishment of local and systemic immunity. Combination immune checkpoint inhibitor and vaccine therapy in mice with advanced disease, characterized by an established suppressive tumor microenvironment, increased the number of mice with non-detectable tumors, however, change in tumor burden compared to vaccine monotherapy was not significant. Vaccination also resulted in tumor clearance in mouse models of metastatic colorectal cancer. This study demonstrates that intraperitoneal vaccine delivery has the potential to enhance vaccine efficacy by activating resident immune cells with the subsequent establishment of protective systemic anti-tumor immunity.

广泛的腹膜播散在妇科或胃肠道癌症患者中很常见。越来越多的证据表明,区域免疫在癌症控制中的核心作用表明,腹腔免疫治疗可能具有治疗优势。本研究描述了由硅化卵巢癌细胞组成的细胞疫苗腹腔内递送与提高生存率相关的免疫机制。在同基因癌症模型中,使用生物发光和荧光成像、显微镜和流式细胞术研究了疫苗从注射部位到乳白色斑点和其他脂肪相关淋巴细胞簇的运输。使用光谱流式细胞术对腹膜免疫细胞群进行表型分析,同时使用肿瘤生物发光成像研究弥散性高级别浆液性卵巢和DNA错配修复精通的微卫星稳定型结直肠癌模型的骨髓和T细胞依赖性、全身免疫和疫苗功效。在卵巢癌小鼠腹腔内接种疫苗后,疫苗细胞被骨髓细胞迅速内化,随后被转运到脂肪相关的淋巴细胞簇。肿瘤清除被证实是T细胞介导的,导致局部和全身免疫的建立。在晚期疾病小鼠中,免疫检查点抑制剂和疫苗联合治疗的特点是建立了抑制性肿瘤微环境,增加了无法检测到肿瘤的小鼠数量,然而,与疫苗单药治疗相比,肿瘤负荷的变化并不显著。在转移性结直肠癌小鼠模型中,疫苗接种也导致肿瘤清除。该研究表明,腹腔注射疫苗有可能通过激活驻留免疫细胞并随后建立保护性全身抗肿瘤免疫来增强疫苗效力。
{"title":"Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration.","authors":"Ben Marwedel, Lorél Y Medina, Henning De May, Joshua E Adogla, Ellie Kennedy, Erica Flores, Eunju Lim, Sarah Adams, Eric Bartee, Rita E Serda","doi":"10.1080/2162402X.2024.2421029","DOIUrl":"10.1080/2162402X.2024.2421029","url":null,"abstract":"<p><p>Widespread peritoneal dissemination is common in patients with gynecologic or gastrointestinal cancers. Accumulating evidence of a central role for regional immunity in cancer control indicates that intraperitoneal immunotherapy may have treatment advantages. This study delineates immune mechanisms engaged by intraperitoneal delivery of a cell-based vaccine comprised of silicified ovarian cancer cells associated with enhanced survival. Vaccine trafficking from the site of injection to milky spots and other fat-associated lymphoid clusters was studied in syngeneic cancer models using bioluminescent and fluorescent imaging, microscopy, and flow cytometry. Spectral flow cytometry was used to phenotype peritoneal immune cell populations, while bioluminescent imaging of cancer was used to study myeloid and T cell dependency, systemic immunity, and vaccine efficacy in models of disseminated high-grade serous ovarian and DNA mismatch-repair proficient microsatellite-stable colorectal cancer. Following intraperitoneal vaccination of mice with ovarian cancer, vaccine cells were rapidly internalized by myeloid cells, with subsequent trafficking to fat-associated lymphoid clusters. Tumor clearance was confirmed to be T cell-mediated, leading to the establishment of local and systemic immunity. Combination immune checkpoint inhibitor and vaccine therapy in mice with advanced disease, characterized by an established suppressive tumor microenvironment, increased the number of mice with non-detectable tumors, however, change in tumor burden compared to vaccine monotherapy was not significant. Vaccination also resulted in tumor clearance in mouse models of metastatic colorectal cancer. This study demonstrates that intraperitoneal vaccine delivery has the potential to enhance vaccine efficacy by activating resident immune cells with the subsequent establishment of protective systemic anti-tumor immunity.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2421029"},"PeriodicalIF":6.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome. 抑制恶性细胞中的 RIPK1 可增强免疫疗法和放疗效果。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-31 Epub Date: 2024-11-04 DOI: 10.1080/2162402X.2024.2425465
Jonathan G Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer

Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptor-interacting serine/threonine-protein kinase 1 (RIPK1). A recent paper in Immunity describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor improved the anticancer efficacy of radiotherapy, immunotherapy (with PD-1 blockade) and radioimmunotherapy (with CTLA-4 blockade).

受体丝氨酸/苏氨酸蛋白激酶1(RIPK1)可抑制细胞凋亡、坏死和依赖于NF-κB的促炎信号传导。最近发表在《免疫》(Immunity)杂志上的一篇论文介绍了一种诱导 RIPK1 蛋白质解体降解的小分子。在临床前实验中,这种 RIPK1 抑制剂提高了放疗、免疫疗法(PD-1 阻断)和放射免疫疗法(CTLA-4 阻断)的抗癌疗效。
{"title":"RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome.","authors":"Jonathan G Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer","doi":"10.1080/2162402X.2024.2425465","DOIUrl":"10.1080/2162402X.2024.2425465","url":null,"abstract":"<p><p>Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptor-interacting serine/threonine-protein kinase 1 (RIPK1). A recent paper in <i>Immunity</i> describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor improved the anticancer efficacy of radiotherapy, immunotherapy (with PD-1 blockade) and radioimmunotherapy (with CTLA-4 blockade).</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2425465"},"PeriodicalIF":6.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell therapy for a rare disease- hairy cell leukemia variant. 一种罕见疾病--毛细胞白血病变体的细胞疗法。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-31 Epub Date: 2024-11-27 DOI: 10.1080/2162402X.2024.2432062
Claire Fritz, Derek P Wong, Philip Rock, Richard Burack, Akshaya Radhakrishnan, Reshmi Parameswaran

Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T cell which binds to all three BAFF receptors, BAFF-receptor, TACI, and BCMA. Here, we demonstrate that HCLv patient-derived cells highly express all three BAFF receptors and that BAFF CAR-T cells induce significant cytotoxicity in vitro against both cell lines and HCL-v patient cells. This cytotoxicity corresponds with significant CAR-T cell activation, degranulation, and release of pro-inflammatory cytokines after co-incubation with HCLv cells. Furthermore, we successfully generated BAFF CAR-T cells directly from an HCLv patient and observed direct autologous killing against patient tumor cells in vitro. These HCLv patient-derived CAR-T cells were also effective in killing the Hair-M cell line and tumor cells derived from a different HCLv patient. Lastly, we also developed two mouse xenograft models for HCL, a subcutaneous Bonna-12 model and intravenous Hair-M xenograft model. We observed decreases in tumor burden and prolonged overall survival without significant toxicity. In conclusion, here we show that BAFF CAR-T cells exert anti-tumor effects in vitro and in vivo against multiple cell lines and patient-derived HCL-v samples and may be a successful therapeutic strategy for HCLv patients.

变异型毛细胞白血病(HCL-v)是一种罕见的克隆成熟B细胞恶性肿瘤,病程慢性。HCL-v患者通常对作为一线疗法的嘌呤核苷类似物产生耐药性。为了解决目前治疗 HCL-v 的不足,我们研究了一种基于 BAFF 配体的 CAR-T 细胞的活性,这种细胞能与 BAFF 受体、TACI 和 BCMA 这三种 BAFF 受体结合。在这里,我们证明了 HCLv 患者衍生细胞高度表达所有三种 BAFF 受体,而且 BAFF CAR-T 细胞在体外对细胞系和 HCL-v 患者细胞都有显著的细胞毒性。在与 HCLv 细胞共孵育后,这种细胞毒性与 CAR-T 细胞的显著活化、脱颗粒和促炎细胞因子的释放相一致。此外,我们还成功地从 HCLv 患者体内直接生成了 BAFF CAR-T 细胞,并在体外观察到了对患者肿瘤细胞的直接自体杀伤作用。这些源自 HCLv 患者的 CAR-T 细胞还能有效杀伤 Hair-M 细胞系和来自另一位 HCLv 患者的肿瘤细胞。最后,我们还开发了两种 HCL 小鼠异种移植模型,即皮下 Bonna-12 模型和静脉注射 Hair-M 异种移植模型。我们观察到肿瘤负荷减轻,总生存期延长,且无明显毒性。总之,我们在此表明,BAFF CAR-T细胞在体外和体内对多种细胞系和患者来源的HCL-v样本具有抗肿瘤作用,可能是HCLv患者的一种成功治疗策略。
{"title":"Cell therapy for a rare disease- hairy cell leukemia variant.","authors":"Claire Fritz, Derek P Wong, Philip Rock, Richard Burack, Akshaya Radhakrishnan, Reshmi Parameswaran","doi":"10.1080/2162402X.2024.2432062","DOIUrl":"10.1080/2162402X.2024.2432062","url":null,"abstract":"<p><p>Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T cell which binds to all three BAFF receptors, BAFF-receptor, TACI, and BCMA. Here, we demonstrate that HCLv patient-derived cells highly express all three BAFF receptors and that BAFF CAR-T cells induce significant cytotoxicity in vitro against both cell lines and HCL-v patient cells. This cytotoxicity corresponds with significant CAR-T cell activation, degranulation, and release of pro-inflammatory cytokines after co-incubation with HCLv cells. Furthermore, we successfully generated BAFF CAR-T cells directly from an HCLv patient and observed direct autologous killing against patient tumor cells in vitro. These HCLv patient-derived CAR-T cells were also effective in killing the Hair-M cell line and tumor cells derived from a different HCLv patient. Lastly, we also developed two mouse xenograft models for HCL, a subcutaneous Bonna-12 model and intravenous Hair-M xenograft model. We observed decreases in tumor burden and prolonged overall survival without significant toxicity. In conclusion, here we show that BAFF CAR-T cells exert anti-tumor effects in vitro and in vivo against multiple cell lines and patient-derived HCL-v samples and may be a successful therapeutic strategy for HCLv patients.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2432062"},"PeriodicalIF":6.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11610546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer. 将免疫细胞死亡诱导剂和 PD-1 阻断剂作为直肠癌的新辅助疗法。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-17 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2416558
Yan Wang, Liwei Zhao, Zhen Zhang, Peng Liu

Immuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.

免疫肿瘤治疗正转向新辅助治疗。对于胃肠道癌症患者,尤其是局部晚期直肠癌患者,新辅助化疗免疫疗法往往能诱导完全反应,从而避免手术干预。最近的临床试验表明,以奥沙利铂为基础的化疗和PD-1/PD-L1靶向免疫疗法的组合可以在手术前安全进行,并达到治愈目的。
{"title":"Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.","authors":"Yan Wang, Liwei Zhao, Zhen Zhang, Peng Liu","doi":"10.1080/2162402X.2024.2416558","DOIUrl":"10.1080/2162402X.2024.2416558","url":null,"abstract":"<p><p>Immuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2416558"},"PeriodicalIF":6.5,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trial watch: anticancer vaccination with dendritic cells. 试验观察:树突状细胞抗癌疫苗。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2412876
Francisca Borges, Raquel S Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Octavie Demeulenaere, Jannes Govaerts, Lisa Kinget, Saurabh Saraswat, Benoit Beuselinck, Steven De Vleeschouwer, Paul Clement, Frederik De Smet, Rüdiger V Sorg, Angeliki Datsi, Nathalie Vigneron, Stefan Naulaerts, Abhishek D Garg

Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.

树突状细胞(DC)是先天性免疫和适应性免疫交叉点上的关键角色,因此是开发抗癌疫苗的理想候选者。基于树突状细胞的免疫疗法通常包括分离患者来源的树突状细胞,用肿瘤相关抗原(TAAs)或肿瘤特异性抗原(TSAs)对其进行脉冲处理,并利用成熟鸡尾酒确保其有效活化。然后再回输这些成熟的 DCs,以激发肿瘤特异性 T 细胞反应。虽然这种方法已证明能产生有效的免疫反应,但由于肿瘤微环境具有免疫抑制作用,其临床疗效一直受到限制。最近的研究重点是增强基于 DC 的疫苗的免疫原性,特别是通过与 T 细胞靶向免疫疗法的联合疗法。本试验观察总结了基于直流电的癌症治疗的最新进展,包括新的临床前和临床策略的开发,并讨论了基于直流电的疫苗在不断发展的免疫肿瘤学领域的未来潜力。
{"title":"Trial watch: anticancer vaccination with dendritic cells.","authors":"Francisca Borges, Raquel S Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Octavie Demeulenaere, Jannes Govaerts, Lisa Kinget, Saurabh Saraswat, Benoit Beuselinck, Steven De Vleeschouwer, Paul Clement, Frederik De Smet, Rüdiger V Sorg, Angeliki Datsi, Nathalie Vigneron, Stefan Naulaerts, Abhishek D Garg","doi":"10.1080/2162402X.2024.2412876","DOIUrl":"https://doi.org/10.1080/2162402X.2024.2412876","url":null,"abstract":"<p><p>Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2412876"},"PeriodicalIF":6.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The landscape of T-cell engagers for the treatment of follicular lymphoma. 治疗滤泡性淋巴瘤的 T 细胞激活剂的前景。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2412869
Alfredo Rivas-Delgado, Ivan Landego, Lorenzo Falchi

Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies.

滤泡淋巴瘤(FL)是非霍奇金淋巴瘤中第二常见的亚型,它的生存和发展依赖于与肿瘤微环境中免疫元素的相互作用,包括T-滤泡辅助细胞和滤泡树突状细胞。尽管 FL 最初对化学免疫疗法有反应,但一般认为它是无法治愈的。改善 FL 免疫介导控制的策略可使这一人群受益匪浅,尤其是其中包括许多老年和合并症患者。免疫细胞诱导剂,尤其是双特异性抗体(BsAbs),通过连接肿瘤和效应细胞,从而引发T细胞活化和细胞毒性杀伤,在靶向治疗FL方面至关重要。CD3 × CD20 BsAbs在B-NHL患者的临床开发中显示出最大的前景,其结构变化会影响其靶向亲和力和效力。本综述总结了目前针对复发/难治 FL 的 BsAbs 临床试验,重点介绍了一些药物的批准情况、它们在一线治疗或联合治疗中的作用、它们的毒性特征以及与其他免疫细胞疗法相比这种治疗方法的前景。
{"title":"The landscape of T-cell engagers for the treatment of follicular lymphoma.","authors":"Alfredo Rivas-Delgado, Ivan Landego, Lorenzo Falchi","doi":"10.1080/2162402X.2024.2412869","DOIUrl":"10.1080/2162402X.2024.2412869","url":null,"abstract":"<p><p>Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2412869"},"PeriodicalIF":6.5,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benzodiazepines compromise the outcome of cancer immunotherapy. 苯二氮卓类药物会影响癌症免疫疗法的效果。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2413719
Léa Montégut, Lisa Derosa, Meriem Messaoudene, Hui Chen, Flavia Lambertucci, Bertrand Routy, Laurence Zitvogel, Isabelle Martins, Guido Kroemer

Acyl CoA binding protein (ACBP, which is encoded by diazepam binding inhibitor, DBI) acts on the gamma-amino butyric acid (GABA) receptor type A via a specific binding site that is shared by diazepam and other benzodiazepines. Both ACBP/DBI and benzodiazepines act as positive allosteric modulators, hence increasing GABA effects on this receptor. Recently, we found that ACBP/DBI acts as an endogenous immunosuppressor, meaning that its antibody-mediated neutralization has immunostimulatory effects and enhances the efficacy of immunotherapy and chemoimmunotherapy in mouse models. Driven by these considerations, we investigated whether diazepam administration in mice would reverse the beneficial effects of ACBP/DBI neutralization on cancer chemoimmunotherapy. Indeed, diazepam abolished the therapeutic of anti-ACBP/DBI antibodies, supporting the idea that diazepam exerts immunosuppressive properties. Of note, treatment with benzodiazepines was associated with poor clinical responses to chemoimmunotherapy in patients with non-small cell lung cancer (NSCLC) as compared to individuals not receiving any psychotropic drugs. Medication with other psychotropic drugs than benzodiazepines did not compromise the outcome of chemoimmunotherapy, indicating that this immunosuppressive effect was benzodiazepine specific. We conclude that benzodiazepines may confer systemic immunosuppression. This hypothesis requires further epidemiological and clinical confirmation.

Acyl CoA 结合蛋白(ACBP,由地西泮结合抑制剂 DBI 编码)通过地西泮和其他苯二氮卓类药物共享的一个特定结合位点作用于γ-氨基丁酸(GABA)受体 A 型。ACBP/DBI 和苯二氮卓类药物都是正异位调节剂,因此能增强 GABA 对该受体的作用。最近,我们发现 ACBP/DBI 是一种内源性免疫抑制剂,这意味着其抗体介导的中和具有免疫刺激作用,并能增强小鼠模型中免疫疗法和化学免疫疗法的疗效。基于这些考虑,我们研究了在小鼠体内施用地西泮是否会逆转 ACBP/DBI 中和对癌症化学免疫疗法的有利影响。事实上,地西泮可消除抗 ACBP/DBI 抗体的治疗作用,这支持了地西泮具有免疫抑制特性的观点。值得注意的是,与未接受任何精神药物治疗的患者相比,接受苯二氮卓类药物治疗的非小细胞肺癌(NSCLC)患者对化学免疫疗法的临床反应较差。除苯二氮卓类药物外,使用其他精神药物也不会影响化学免疫疗法的效果,这表明这种免疫抑制效应是苯二氮卓类的特异性效应。我们的结论是,苯二氮卓类药物可能会导致全身性免疫抑制。这一假设需要进一步的流行病学和临床证实。
{"title":"Benzodiazepines compromise the outcome of cancer immunotherapy.","authors":"Léa Montégut, Lisa Derosa, Meriem Messaoudene, Hui Chen, Flavia Lambertucci, Bertrand Routy, Laurence Zitvogel, Isabelle Martins, Guido Kroemer","doi":"10.1080/2162402X.2024.2413719","DOIUrl":"https://doi.org/10.1080/2162402X.2024.2413719","url":null,"abstract":"<p><p>Acyl CoA binding protein (ACBP, which is encoded by <i>diazepam binding inhibitor</i>, <i>DBI</i>) acts on the gamma-amino butyric acid (GABA) receptor type A via a specific binding site that is shared by diazepam and other benzodiazepines. Both ACBP/DBI and benzodiazepines act as positive allosteric modulators, hence increasing GABA effects on this receptor. Recently, we found that ACBP/DBI acts as an endogenous immunosuppressor, meaning that its antibody-mediated neutralization has immunostimulatory effects and enhances the efficacy of immunotherapy and chemoimmunotherapy in mouse models. Driven by these considerations, we investigated whether diazepam administration in mice would reverse the beneficial effects of ACBP/DBI neutralization on cancer chemoimmunotherapy. Indeed, diazepam abolished the therapeutic of anti-ACBP/DBI antibodies, supporting the idea that diazepam exerts immunosuppressive properties. Of note, treatment with benzodiazepines was associated with poor clinical responses to chemoimmunotherapy in patients with non-small cell lung cancer (NSCLC) as compared to individuals not receiving any psychotropic drugs. Medication with other psychotropic drugs than benzodiazepines did not compromise the outcome of chemoimmunotherapy, indicating that this immunosuppressive effect was benzodiazepine specific. We conclude that benzodiazepines may confer systemic immunosuppression. This hypothesis requires further epidemiological and clinical confirmation.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2413719"},"PeriodicalIF":6.5,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance. 酰基辅酶A结合蛋白(ACBP):自噬检查点,可作为改善癌症免疫监视的靶点。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2413200
Léa Montégut, Isabelle Martins, Guido Kroemer

Acyl CoA binding protein (ACBP) encoded by DBI is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in Molecular Cancer that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.

由DBI编码的酰基辅酶A结合蛋白(ACBP)是一种组织激素,可限制多种类型细胞的自噬,从而起到细胞外自噬检查点的作用。我们最近在《分子癌症》(Molecular Cancer)杂志上报道,中和 ACBP 的单克隆抗体能改善乳腺癌和肺癌的免疫监视。此外,在临床前模型中,中和 ACBP 可改善 PD-1 阻断新辅助化疗免疫疗法的疗效。
{"title":"Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance.","authors":"Léa Montégut, Isabelle Martins, Guido Kroemer","doi":"10.1080/2162402X.2024.2413200","DOIUrl":"10.1080/2162402X.2024.2413200","url":null,"abstract":"<p><p>Acyl CoA binding protein (ACBP) encoded by <i>DBI</i> is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in <i>Molecular Cancer</i> that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2413200"},"PeriodicalIF":6.5,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy. 调节性 T 细胞消灭 cDC1 细胞会危及癌症免疫疗法。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2412874
Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp

Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (TR1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

最近的研究结果表明,新抗原特异性细胞毒性1型调节性T(TR1)CD4 T细胞可以通过杀伤呈现与MHC II类结合的肿瘤抗原的1型常规树突状细胞(cDC1s)来颠覆癌症免疫疗法。这凸显了 cDC1s 在激发抗癌免疫力方面的重要性,但也带来了新的临床挑战。
{"title":"Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy.","authors":"Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp","doi":"10.1080/2162402X.2024.2412874","DOIUrl":"10.1080/2162402X.2024.2412874","url":null,"abstract":"<p><p>Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (T<sub>R</sub>1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2412874"},"PeriodicalIF":6.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors. 肽引导的适配体-CAR T 细胞疗法用于治疗表达 SSTR2 的神经内分泌肿瘤。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-10-03 eCollection Date: 2024-01-01 DOI: 10.1080/2162402X.2024.2412371
Christian Pellegrino, Nicholas Favalli, Laura Volta, Ramon Benz, Sara Puglioli, Gabriele Bassi, Kathrin Zitzmann, Christoph Josef Auernhammer, Svenja Nölting, Chiara F Magnani, Dario Neri, Felix Beuschlein, Markus G Manz

Somatostatin receptor type 2 (SSTR2) is one of the five subtypes of somatostatin receptors and is overexpressed on the surface of most gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), pituitary tumors, paraganglioma, and meningioma, as well as hepatocellular carcinoma and breast cancer. Chimeric antigen receptor (CAR) T-cells are genetically engineered to express an artificial, T-cell activating binder, leading upon ligation to biocidal activity against target-antigen expressing cells. Adaptor-CAR T-cells recognize, via the CAR, a tag on an antigen-binding molecule, building an activating bridge between the CAR and the target cell. We hypothesized that a novel fluorescent-peptide antagonist of SSTR2, called Octo-Fluo, in combination with anti-FITC adaptor CAR (AdFITC(E2)-CAR) T-cells, may function as an on-off tunable activating bridge between the CAR and SSTR2 expressing target cells. In vitro studies confirmed the binding of Octo-Fluo to Bon1-SSTR2 mCherry-Luc cells without evidence of internalization. AdFITC(E2)-CAR T-cells were activated and efficiently induced Bon1-SSTR2 cell death in vitro, in an Octo-Fluo concentration-dependent manner. Similarly, AdFITC(E2)-CAR T-cells in combination with Octo-Fluo efficiently infiltrated the tumor and eliminated Bon1-SSTR2 tumors in immunodeficient mice in therapeutic settings. Both, AdFITC(E2)-CAR T-cell tumor infiltration and biocidal activity were Octo-Fluo concentration-dependent, with high doses of Octo-Fluo, saturating both the CAR and the SSTR2 antigen independently, leading to the loss of tumor infiltration and biocidal activity due to the loss of bridge formation. Our findings demonstrate the potential of using AdFITC(E2)-CAR T-cells with Octo-Fluo as a versatile, on-off tunable bispecific adaptor for targeted CAR T-cell immunotherapy against SSTR2-positive NETs.

体生长抑素受体 2 型(SSTR2)是体生长抑素受体的五种亚型之一,在大多数胃肠胰神经内分泌肿瘤(GEP-NET)、垂体瘤、副神经节瘤、脑膜瘤以及肝细胞癌和乳腺癌的表面过度表达。嵌合抗原受体(CAR)T 细胞经过基因工程改造,表达一种人工的 T 细胞活化粘合剂,在连接后对表达靶抗原的细胞产生生物杀伤活性。适配器-CAR T 细胞通过 CAR 识别抗原结合分子上的标签,在 CAR 和靶细胞之间架起一座激活桥梁。我们假设,一种名为 Octo-Fluo 的新型 SSTR2 荧光肽拮抗剂与抗 FITC 适配 CAR(AdFITC(E2)-CAR)T 细胞结合,可以在 CAR 和表达 SSTR2 的靶细胞之间起到开关可调的激活桥梁作用。体外研究证实,Octo-Fluo 可与 Bon1-SSTR2 mCherry-Luc 细胞结合,但无内化迹象。AdFITC(E2)-CAR T 细胞在体外被激活并有效诱导 Bon1-SSTR2 细胞死亡,其方式与 Octo-Fluo 浓度有关。同样,在治疗过程中,AdFITC(E2)-CAR T 细胞与 Octo-Fluo 结合使用可有效渗透肿瘤,并消除免疫缺陷小鼠的 Bon1-SSTR2 肿瘤。AdFITC(E2)-CAR T 细胞的肿瘤浸润和生物杀伤活性都与 Octo-Fluo 的浓度有关,高剂量的 Octo-Fluo 会使 CAR 和 SSTR2 抗原独立达到饱和,从而导致肿瘤浸润和生物杀伤活性因桥的形成而丧失。我们的研究结果表明,AdFITC(E2)-CAR T细胞与Octo-Fluo可作为一种多功能、开关可调的双特异性适配体,用于针对SSTR2阳性NET的靶向CAR T细胞免疫疗法。
{"title":"Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.","authors":"Christian Pellegrino, Nicholas Favalli, Laura Volta, Ramon Benz, Sara Puglioli, Gabriele Bassi, Kathrin Zitzmann, Christoph Josef Auernhammer, Svenja Nölting, Chiara F Magnani, Dario Neri, Felix Beuschlein, Markus G Manz","doi":"10.1080/2162402X.2024.2412371","DOIUrl":"https://doi.org/10.1080/2162402X.2024.2412371","url":null,"abstract":"<p><p>Somatostatin receptor type 2 (SSTR2) is one of the five subtypes of somatostatin receptors and is overexpressed on the surface of most gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), pituitary tumors, paraganglioma, and meningioma, as well as hepatocellular carcinoma and breast cancer. Chimeric antigen receptor (CAR) T-cells are genetically engineered to express an artificial, T-cell activating binder, leading upon ligation to biocidal activity against target-antigen expressing cells. Adaptor-CAR T-cells recognize, via the CAR, a tag on an antigen-binding molecule, building an activating bridge between the CAR and the target cell. We hypothesized that a novel fluorescent-peptide antagonist of SSTR2, called Octo-Fluo, in combination with anti-FITC adaptor CAR (AdFITC(E2)-CAR) T-cells, may function as an on-off tunable activating bridge between the CAR and SSTR2 expressing target cells. In vitro studies confirmed the binding of Octo-Fluo to Bon1-SSTR2 mCherry-Luc cells without evidence of internalization. AdFITC(E2)-CAR T-cells were activated and efficiently induced Bon1-SSTR2 cell death in vitro, in an Octo-Fluo concentration-dependent manner. Similarly, AdFITC(E2)-CAR T-cells in combination with Octo-Fluo efficiently infiltrated the tumor and eliminated Bon1-SSTR2 tumors in immunodeficient mice in therapeutic settings. Both, AdFITC(E2)-CAR T-cell tumor infiltration and biocidal activity were Octo-Fluo concentration-dependent, with high doses of Octo-Fluo, saturating both the CAR and the SSTR2 antigen independently, leading to the loss of tumor infiltration and biocidal activity due to the loss of bridge formation. Our findings demonstrate the potential of using AdFITC(E2)-CAR T-cells with Octo-Fluo as a versatile, on-off tunable bispecific adaptor for targeted CAR T-cell immunotherapy against SSTR2-positive NETs.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2412371"},"PeriodicalIF":6.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncoimmunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1